Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 20/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787929 | 1.00 | CCNA2 (1.00) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL1882254 | 1.00 | CCNA2 (1.00) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6792018 | 0.97 | CCNA2 (0.94) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6787696 | 0.97 | CCNA2 (0.94) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6786815 | 0.97 | CCNA2 (0.94) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6787738 | 0.97 | CCNA2 (1.00) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6788676 | 0.89 | CCNA2 (0.79) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6794234 | 0.89 | CCNA2 (0.79) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6789077 | 0.86 | CCNA2 (0.87) | CCNA2CDK2CCNA1CCNB2CCNE2 | |
| SCHEMBL6789478 | 0.86 | CCNA2 (0.75) | CCNA2CDK2CCNA1CCNB2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-01-29 | — | — | US | claimed |
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| EP-2073802-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073807-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2073803-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2049119-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3-[3-(5-MORPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL)-1H-1-PYRAZOL-4-YL]-UREA | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| EP-2046330-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2037931-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | Astex Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| EP-2026805-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | Astex Therapeutics Limited (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008044041-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008001115-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3- (5-M0RPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL) -LH-1-PYRAZOL- 4-YL] -UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007129062-A1 | PHARMACEUTICAL COMBINATIONS OF DIAZOLE DERIVATIVES FOR CANCER TREATMENT | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007125310-A2 | PHARMACEUTICAL COMBINATIONS OF PK INHIBITORS AND OTHER ACTIVE AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1845975-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845973-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | PHARMACIA ITALIA SPA (IT) | 2004-01-29 | — | — | US | disclosed |
| EP-1345909-A1 | PHENYLACETAMIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002048114-A1 | PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019046-A1 | Phenylacetamido-pyrazole derivatives and their use as antitumor agents | DCK, CCNK, CDK2 | CCNA2 120/4885CDK2 3/4885CCNA1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.